Caricamento...
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
BACKGROUND: Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, and their large size may limit their tumor penetration, leading to suboptimal eff...
Salvato in:
| Pubblicato in: | J Immunother Cancer |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6805442/ https://ncbi.nlm.nih.gov/pubmed/31640814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0705-y |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|